EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Results from the Survey of Antibiotic Resistance (SOAR) 2018–21 in Türkiye: data based on CLSI, EUCAST (dose-specific) and pharmacokinetic/pharmacodynamic (PK/PD) breakpoints

Didem Torumkuney, Nergis Keles, Ufuk Hasdemir, Gülşen Hazırolan, Sohret Aydemir, Zerrin Aktas, Oral Oncul, Ian Morrissey, Anand Manoharan

Journal of Antimicrobial Chemotherapy · 2025

DOI: 10.1093/jac/dkaf289 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Antimicrobial Chemotherapy, 2025. Verfasst von Didem Torumkuney und 8 weiteren Autor:innen. Beteiligte Einrichtung: Infectious Diseases Research Unit, GSK, London, UK. Hauptthemen laut MEDLINE: Haemophilus influenzae, Anti-Bacterial Agents, Streptococcus pneumoniae, Respiratory Tract Infections. Die Arbeit nennt 23 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: GSK, Ashfield MedComms, Inizio company.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objectives

To determine the antibiotic susceptibility of Streptococcus pneumoniae and Haemophilus influenzae from community-acquired respiratory tract infections from four hospitals in Türkiye in 2018–21.

Methods

MICs were determined by CLSI methodology, and susceptibility was interpreted using CLSI, EUCAST and pharmacokinetic/pharmacodynamic (PK/PD) breakpoints.

Results

S. pneumoniae (n = 142) and H. influenzae (n = 315) isolates were collected. Penicillin susceptibility in pneumococci was 35.9% by CLSI oral/EUCAST low-dose breakpoints and 82.4% by EUCAST high-dose/CLSI intravenous administration. Similar susceptibility (78.2%–82.4%, CLSI) was observed for ceftriaxone, amoxicillin/clavulanic acid, amoxicillin and cefotaxime. Other cephalosporins, tetracyclines, macrolides and trimethoprim/sulfamethoxazole were poorly active (42.3%–59.2%); fluoroquinolones (≥97.9%) were most active. Susceptibility by EUCAST was lower for high-dose amoxicillin (64.8%), high-dose amoxicillin/clavulanic acid (59.2%) and cefaclor (0%), but higher for high-dose ceftriaxone (99.3%). High-dose PK/PD breakpoints for amoxicillin and amoxicillin/clavulanic acid increased susceptibility (87.3% and 88.0%). Most H. influenzae were β-lactamase negative (n = 294, 93.3%); 26 (8.3%) were β-lactamase-negative ampicillin-resistant by EUCAST breakpoints and eight (2.5%) by CLSI breakpoints. Antibiotic susceptibility was ≥91.8% (CLSI) except ampicillin (85.4%) and trimethoprim/sulfamethoxazole (64.1%). EUCAST or PK/PD breakpoint susceptibility was similar, except for oral cefuroxime (0% EUCAST, 71.7% PK/PD and 99.4% CLSI) and macrolides (no EUCAST breakpoint, 1.0%–2.5% PK/PD and 96.5%–99.1% CLSI).

Conclusions

Susceptibility in S. pneumoniae was <60% except for fluoroquinolones, amoxicillin and amoxicillin/clavulanic acid, cefotaxime and ceftriaxone. H. influenzae susceptibility to most antibiotics was >90% except for trimethoprim/sulfamethoxazole and ampicillin. These data are similar to recent surveillance of antibiotic resistance data in Türkiye.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Haemophilus influenzaeAnti-Bacterial AgentsStreptococcus pneumoniaeRespiratory Tract InfectionsDrug Resistance, BacterialHumansMicrobial Sensitivity TestsCommunity-Acquired InfectionsMiddle AgedAdultMaleFemaleAgedYoung AdultChildChild, PreschoolHaemophilus InfectionsAdolescentInfantPneumococcal Infections

Substanzen

Anti-Bacterial Agents

Autor:innen und Institutionen

  • Infectious Diseases Research Unit, GSK, London, UK.
  • Infectious Diseases Medical & Scientific Affairs, GSK, Istanbul, Türkiye.
  • Department of Medical Microbiology, Marmara University School of Medicine, Pendik Training and Research Hospital, Istanbul, Türkiye.
  • Department of Medical Microbiology, Hacettepe University Faculty of Medicine, Ankara, Türkiye.
  • Department of Clinical Microbiology, Faculty of Medicine, Ege University, Izmir, Türkiye.
  • Department of Clinical Microbiology, Istanbul Faculty of Medicine, Istanbul University, Istanbul, Türkiye.

Förderung

  • GSK
  • Ashfield MedComms
  • Inizio company

Zitieren

APA

Torumkuney, D., Keles, N., Hasdemir, U., Hazırolan, G., Aydemir, S., Aktas, Z., Oncul, O., Morrissey, I., & Manoharan, A. (2025). Results from the Survey of Antibiotic Resistance (SOAR) 2018–21 in Türkiye: data based on CLSI, EUCAST (dose-specific) and pharmacokinetic/pharmacodynamic (PK/PD) breakpoints. Journal of Antimicrobial Chemotherapy. https://doi.org/10.1093/jac/dkaf289

Vancouver

Torumkuney D, Keles N, Hasdemir U, Hazırolan G, Aydemir S, Aktas Z, et al. Results from the Survey of Antibiotic Resistance (SOAR) 2018–21 in Türkiye: data based on CLSI, EUCAST (dose-specific) and pharmacokinetic/pharmacodynamic (PK/PD) breakpoints. Journal of Antimicrobial Chemotherapy. 2025. doi:10.1093/jac/dkaf289

BibTeX
@article{Torumkuney2025,
  author = {Torumkuney, Didem and Keles, Nergis and Hasdemir, Ufuk and Hazırolan, Gülşen and Aydemir, Sohret and Aktas, Zerrin and Oncul, Oral and Morrissey, Ian and Manoharan, Anand},
  title = {Results from the Survey of Antibiotic Resistance (SOAR) 2018–21 in Türkiye: data based on CLSI, EUCAST (dose-specific) and pharmacokinetic/pharmacodynamic (PK/PD) breakpoints},
  journal = {Journal of Antimicrobial Chemotherapy},
  year = {2025},
  doi = {10.1093/jac/dkaf289}
}
Kostenlos starten →